Wexford Capital LP Satsuma Pharmaceuticals, Inc. Transaction History

Wexford Capital LP

  • $382 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021
SELL
$4.57 - $7.18 $38,228 - $60,060
-8,365 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$3.56 - $5.09 $29,779 - $42,577
8,365 New
8,365 $39,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Wexford Capital LP Portfolio

Follow Wexford Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Wexford Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email